1.a. Full Title: CRP and Venous Thromboembolism Incidence

b. Abbreviated Title (Length 26 characters): CRP and VTE

2. Writing Group:
   Writing group members: Aaron Folsom, Pam Lutsey, Brad Astor, Mary Cushman

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. ___AF___ [please confirm with your initials electronically or in writing]

First author:
Address: Division of Epidemiology and Community Health
University of Minnesota

Phone: 612-626-8862 Fax: 612-624-0315
E-mail: folso001@umn.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name:
Address:

Phone: Fax:
E-mail:

3. Timeline: finish by July 09

4. Rationale:
Inflammation is generally not believed to be important in the etiology of venous thromboembolism (VTE), and most (2,3,7) but not all studies (5) have found no independent association of VTE with CRP or with CRP polymorphisms (1,4). We also found no association of CRP with VTE in a previous LITE nested case control study (6).
The recent addition of CRP to the ARIC visit 4 measurements allows us to re-test this hypothesis. There are over 260 VTE events in ARIC since visit 4, which will provide adequate power for detecting a moderate association. This likely will be a letter or brief report.

5. Main Hypothesis/Study Questions:

CRP at visit 4 is associated positively with incidence of VTE. We expect any univariate association may be explained by obesity.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Design: cohort
Endpoint: VTE incidence
Exposure: visit 4 CRP
Main covariates: age, race, sex, center, BMI
Analysis: Cox proportional hazards, with CRP modeled as a continuous variable and as quartiles. Also look at high (e.g. >90%) CRP vs. low.

REFERENCES


7.a. Will the data be used for non-CVD analysis in this manuscript? ___ Yes  _X___ No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used? ___ Yes _____ No
   (This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? ___ Yes  _X___ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”? ___ Yes ___ No

8.c. If yes, is the author aware that the participants with RES_DNA = ‘not for profit’ restriction must be excluded if the data are used by a for profit group? ___ Yes ___ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.csec.unc.edu/ARIC/search.php
   ___X___ Yes  _______ No
   Other than ref 6, cited above.

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?
11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?  
   x Yes  No

11.b. If yes, is the proposal
   x A. primarily the result of an ancillary study (list number* 1998.03 and 2006.16)
   ___ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* __________ __________)

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.